Together these studies establish ferroptosis as a potential therapeutic opportunity in luminal BC, the HER2 pathway as a mechanism of resistance to ferroptosis, and irreversible HER2 inhibitors as an approach to overcome intrinsic resistance to ferroptosis in luminal BC. Here, ERBB2 is linked to breast cancer.